Twist Bioscience Corporation's New Acquisition to Help Create Better Design and Build of Synthetic DNA
FREMONT, CA: Twist Bioscience Corporation, a developer of semiconductor-based synthetic DNA manufacturing process, acquires Genome Compiler Corporation, a provider of an intuitive all-in-one software platform for genetic engineers, molecular and synthetic biologists. By bringing the Genome Compiler technology, network and expert team into the Twist Bioscience organization, the company intends to build digital products portfolio, including an eCommerce solution with gene design capabilities.
Genetic engineering or genetic modification refers to the set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to produce improved or novel organisms. In the space of biotechnology, use of genetic engineering has resulted in new accomplishments that herald a better future in the fields of research, agriculture, industrial biotechnology, and medicine.
By carrying out the process of DNA synthesis on silicon-based DNA writing platform, Twist Bioscience is providing researchers access to high quality oligonucleotides, genes and libraries with low cost and less time requirement. Using this innovative platform, superior-quality and high throughput synthetic gene can be produced which in turn will lead to creation of advanced personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics, biodetection and data storage. As part of the agreement, the Genome Compiler research and development center in Israel will become Twist Bioscience's first international site for synthetic and molecular biology experiments leveraging the Genome compiler technology.
Genome Compiler Corporation’s Genome Compiler is a genetic design software that provides comprehensive set of tools for DNA design and visualization, data management, and collaboration. For instance, to deal with the life threatening disease like dengue that has infected millions of people in the recent past with the count still increasing, a genetically engineered sterile male mosquito was created by Oxitec Ltd. as part of their experiment that was intended bring an end to the dengue causing mosquito population. The experiment resulted in 90 percent reduction of trial mosquito population on whom the test was conducted. By changing the genetic information encoded in DNA, researchers have been able to achieve many milestones from finding cure for serious diseases to producing high yielding crops.
"We are extremely excited to join forces with Twist Bioscience. By combining our advanced software design capabilities with the technology leader in DNA synthesis, our customers will be able to streamline the design-build-test cycle. We believe the synthetic and molecular biology communities will find the integrated offering a great platform to accelerate their research," says Omri Amirav-Drory, Ph.D., founder and CEO, Genome Compiler.